Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 5Breast 4Other hematologic neoplasm 3Lymphoid 3Plasma cell 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Dermatologic 1CNS 1

Conditions

Glioma 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Palonosetron × CNS × Clear all
NCT00900757 2019-08-28

Intravenous Palonosetron With Radiotherapy and Concomitant Temozolomide

Duke University

Phase 2 Completed
57 enrolled 10 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡